Collegium Pharmaceutical, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +19.9%
EBITDA: +83.3%
EBIT: +33.6%
EPS: +69.8%
Free cash flow: +67.8%
Operating cash flow: +66.8%

Forward estimates

Revenue: +27.1%
EBITDA: -33.6%
EPS: +250.1%

Three-year CAGR

Revenue: +18.9%
EBITDA: +32.3%
EBIT: +77.7%
Net income: +14.3%
EPS: +11.2%
Free cash flow: +38.8%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.